Author:
Chen Lihua,Li Jiajia,Wu Xiaohua,Zheng Zhong
Abstract
BackgroundThe genomic abnormalities associated with uterine leiomyosarcoma (uLMS) have not been fully elucidated to date.ObjectiveTo understand the pathogenesis of uLMS and to identify driver mutations and potential therapeutic targets in uLMS.MethodsThree matched tumor-constitutional DNA pairs from patients with recurrent uLMS were subjected to whole-exome capture and next-generation sequencing. The role of the selected gene SHARPIN in uLMS was analyzed by the CCK-8 assay and colony formation assay after specific siRNA knockdown.ResultsWe identified four genes with somatic SNVs, namely, SLC39A7, GPR19, ZNF717, and TP53, that could be driver mutations. We observed that 30.7% (4/13) of patients with uLMS had TP53 mutations as analyzed by direct sequencing. Analysis of somatic copy number variants (CNVs) showed regions of chromosomal gain at 1q21-23, 19p13, 17q21, and 17q25, whereas regions of chromosomal loss were observed at 2q35, 2q37, 1p36, 10q26, 6p22, 8q24, 11p15, 11q12, and 9p21. The SHARPIN gene was amplified in two patients and mutated in another (SHARPIN: NM_030974: exon2: c.G264C, p.E88D). Amplification of the SHARPIN gene was associated with shorter PFS and OS in soft tissue sarcoma, as shown by TCGA database analysis. Knockdown of SHARPIN expression was observed to decrease cell growth and colony formation in uterine sarcoma cell lines.ConclusionsExome sequencing revealed mutational heterogeneity of uLMS. The SHARPIN gene was amplified in uLMS and could be a candidate oncogene.
Reference38 articles.
1. Prognostic Factors and Survival in Patients Treated Surgically for Primary and Recurrent Uterine Leiomyosarcoma: A Single Center Experience;Bacalbasa;Anticancer Res,2015
2. Management of Advanced Uterine Leiomyosarcoma;Hyman;Curr Opin Oncol,2014
3. Secondary Cytoreductive Surgery in Recurrent Uterine Leiomyosarcoma: A Multi-Institutional Study;Bizzarri;Int J gynecological Cancer Off J Int Gynecological Cancer Soc,2019
4. Current State of the Art and Emerging Pharmacotherapy for Uterine Leiomyosarcomas;Tantari;Expert Opin Pharmacother,2019
5. Pazopanib for Metastatic Soft-Tissue Sarcoma (Palette): A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial;van der Graaf;Lancet,2012
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献